Entering text into the input field will update the search result below

SciSparc to expand mid-stage trial of Tourette Syndrome treatment to U.S. clinical site

Jul. 08, 2022 9:20 AM ETSciSparc Ltd. (SPRC)By: Anuron Mitra, SA News Editor
  • Israel-based SciSparc (NASDAQ:SPRC) on Friday said it had started the process of preparing for an investigational new drug application for its phase 2b trial evaluating its SCI-110 drug candidate for Tourette Syndrome.
  • As part of the process, the company will expand

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.